Fortress Biotech Announces Final Patient Dosed in Phase 1B Trial of CAEL-101 for the Treatment of AL Amyloidosis

View Press Release (PDF) CAEL-101 is in development by Fortress subsidiary Caelum Biosciences  Preliminary Phase 1b data expected mid-2017; full data readout anticipated in late 2017  Phase 2 study planned for the first half of 2018  NEW YORK, NY – May 4, 2017 – Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that study sponsor Columbia

Read More

Fortress Biotech Announces Orphan Drug Designations for CAEL-101 in Amyloidosis

View Press Release (PDF) FDA acknowledges transfer to Caelum Biosciences, a Fortress Biotech Company New York, NY – April 5, 2017 – Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that the U.S. Department of Health & Human Services has confirmed the transfer of two U.S. Food and Drug Administration (FDA) Orphan Drug Designations for CAEL-101

Read More

Fortress Biotech forms a new subsidiary, Caelum Biosciences, Inc., to develop a novel treatment for AL Amyloidosis

Download the Press Release (PDF) Caelum Program Evaluating CAEL‐101 (11‐1F4) for AL Amyloidosis In‐licensed from Columbia University Data from ongoing Phase 1a/1b study of CAEL‐101 presented by Dr. Suzanne Lentzsch at ASH have demonstrated CAEL‐101 is safe and well tolerated; 67 percent of patients showed improvement in organ function. Michael Spector to Serve as Chief Executive Officer NEW YORK, NY – January 4, 2017 – Fortress Biotech, Inc. (Nasdaq: FBIO)

Read More